Drug Information

Drug (ID: DG00011) and It's Reported Resistant Information

Name	Dolutegravir
Synonyms	1051375-16-6; GSK1349572; Tivicay; S/GSK1349572; Dolutegravir (GSK1349572); S-349572; GSK-1349572; GSK 1349572; UNII-DKO1W9H7M1; (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide; CHEBI:76010; DKO1W9H7M1; Tivicay (TN); (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; Dolutegravir Sodium ( Click to Show/Hide
Indication	In total 1 Indication(s) Human immunodeficiency virus disease [ICD-11: 1C60-1C62] Approved [1]
Structure
Drug Resistance Disease(s)	Disease(s) with Clinically Reported Resistance for This Drug (1 diseases) HIV infection [ICD-11: 1C62] [2] *Disease(s) with Resistance Information Validated by in-vivo* Model for This Drug** (1 diseases) HIV infection [ICD-11: 1C62] [3]
Target	Human immunodeficiency virus Integrase (HIV IN)	POL_HV1B1	[1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula	C20H19F2N3O5
IsoSMILES	C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
InChI	1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1
InChIKey	RHWKPHLQXYSBKR-BMIGLBTASA-N
PubChem CID	54726191
ChEBI ID	CHEBI:76010
TTD Drug ID	D00YZD
VARIDT ID	DR00383
DrugBank ID	DB08930

Type(s) of Resistant Mechanism of This Drug

ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-01: Infectious/parasitic diseases

Click to Show/Hide the Resistance Disease of This Class

HIV infection [ICD-11: 1C62]

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Aberration of the Drug's Therapeutic Target (ADTT)			Click to Show/Hide
Key Molecule: HIV1 Integrase (HIV1 IT)				[4]
Molecule Alteration	Missense mutation		p.S17N+p.V32I+p.I36V+p.D41G+p.M50L+p.I72V+p.L101I+p.T124N+p.T125A+p.I135V+p.V201I+p.I208L+p.D256E	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Q148N, a novel integrase inhibitor resistance mutation associated with low-level reduction in elvitegravir susceptibility.
Key Molecule: HIV1 Integrase (HIV1 IT)				[4]
Molecule Alteration	Missense mutation		p.I72V+p.I113V+p.G140S+p.Q148H+p.V151I+p.L234V	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Q148N, a novel integrase inhibitor resistance mutation associated with low-level reduction in elvitegravir susceptibility.
Key Molecule: HIV1 Integrase (HIV1 IT)				[5]
Molecule Alteration	Missense mutation		p.I72V+p.I113V+p.V151I+p.L234V+p.R263K	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Our results show that the R263k substitution decreased HIV-1 subtype C susceptibility to DTG and EVG by 3.3 and 50-fold, respectively. In subtype B, R263k conferred a somewhat lesser degree of drug resistance, that is, 2.1 and 25-fold decreases in susceptibility to DTG and EVG, respectively. R263k did not confer resistance against RAL in HIV-1 subtype C in accordance with results for subtype B.
Key Molecule: HIV1 Integrase (HIV1 IT)				[5]
Molecule Alteration	Missense mutation		p.K14R+p.D25E+p.V31I+p.L45S+p.I72V+p.E96D+p.F100Y+p.L101I+p.T112V+p.T124A+p.T125A+p.K136Q+p.V201I+p.K219N+p.N222K+p.L234I+p.R263K+p.A265V+p.R269K+p.D278A	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Our results show that the R263k substitution decreased HIV-1 subtype C susceptibility to DTG and EVG by 3.3 and 50-fold, respectively. In subtype B, R263k conferred a somewhat lesser degree of drug resistance, that is, 2.1 and 25-fold decreases in susceptibility to DTG and EVG, respectively. R263k did not confer resistance against RAL in HIV-1 subtype C in accordance with results for subtype B.
Key Molecule: HIV1 Integrase (HIV1 IT)				[3]
Molecule Alteration	Missense mutation		p.I72V+p.I113V+p.G118R+p.E138K+p.V151I+p.L234V	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
In Vitro Model	BL21 cells	Cerebrospinal fluid	Homo sapiens (Human)	CVCL_M639
Experiment for Molecule Alteration	Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[3]
Molecule Alteration	Missense mutation		p.I72V+p.I113V+p.G118R+p.V151I+p.L234V	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
In Vitro Model	BL21 cells	Cerebrospinal fluid	Homo sapiens (Human)	CVCL_M639
Experiment for Molecule Alteration	Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[3]
Molecule Alteration	Missense mutation		p.H51Y+p.I72V+p.I113V+p.V151I+p.L234V	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
In Vitro Model	BL21 cells	Cerebrospinal fluid	Homo sapiens (Human)	CVCL_M639
Experiment for Molecule Alteration	Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[3]
Molecule Alteration	Missense mutation		p.E11D+p.K14R+p.S24N+p.V31I+p.M50I+p.L74I+p.A91E+p.L101I+p.T112V+p.G118R+p.S119R+p.T124A+p.T125A+p.A133T+p.G134N+p.I135V+p.K136T+p.E138K+p.V165I+p.V201I+p.T206S+p.T218I+p.L234I+p.S283D	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
In Vitro Model	BL21 cells	Cerebrospinal fluid	Homo sapiens (Human)	CVCL_M639
Experiment for Molecule Alteration	Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[3]
Molecule Alteration	Missense mutation		p.E11D+p.K14R+p.S24N+p.V31I+p.M50I+p.L74I+p.A91E+p.L101I+p.T112V+p.G118R+p.S119R+p.T124A+p.T125A+p.A133T+p.G134N+p.I135V+p.K136T+p.V165I+p.V201I+p.T206S+p.T218I+p.L234I+p.S283D	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
In Vitro Model	BL21 cells	Cerebrospinal fluid	Homo sapiens (Human)	CVCL_M639
Experiment for Molecule Alteration	Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[3]
Molecule Alteration	Missense mutation		p.E11D+p.K14R+p.S24N+p.V31I+p.M50I+p.H51Y+p.L74I+p.A91E+p.L101I+p.T112V+p.S119R+p.T124A+p.T125A+p.A133T+p.G134N+p.I135V+p.K136T+p.V165I+p.V201I+p.T206S+p.T218I+p.L234I+p.S283D	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
In Vitro Model	BL21 cells	Cerebrospinal fluid	Homo sapiens (Human)	CVCL_M639
Experiment for Molecule Alteration	Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[2]
Molecule Alteration	Missense mutation		p.R20K+p.V31I+p.L45I+p.L101I+p.I135IV+p.N155H+p.E157Q+p.K160Q+p.V201I+p.K215N+p.A265V	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	RT-PCR; Sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Five mutations (A49P, L68FL, T97A, E138k and L234V) were implicated in emergent dolutegravir resistance, with a concomitant severe compromise in viral replicative capacity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[2]
Molecule Alteration	Missense mutation		p.R20K+p.V31I+p.L45I+p.L101I+p.K111KR+p.I135IV+p.E157Q+p.K160Q+p.V201I+p.K215N+p.A265AV	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	RT-PCR; Sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Five mutations (A49P, L68FL, T97A, E138k and L234V) were implicated in emergent dolutegravir resistance, with a concomitant severe compromise in viral replicative capacity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[6]
Molecule Alteration	Missense mutation		p.L101I+p.T125A+p.I135V+p.D167DE+p.G193R+p.V201I+p.I208L+p.K211T+p.A265V+p.S283G	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	MT-2 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2631
	MT-4 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2632
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.Q148K+p.D232N	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E296Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.E10D+p.S17T+p.S39N+p.I72V+p.S119P+p.T122I+p.T124N+p.T125A+p.V151I+p.N155H+p.N222K+p.P261A	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q194H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.D6T+p.K7E+p.S17N+p.V54I+p.I72V+p.L74M+p.V79I+p.T97A+p.L101I+p.I113L+p.S119R+p.T122I+p.T124N+p.T125A+p.E138K+p.G140A+p.I141AT+p.S147SG+p.Q148R+p.K156N+p.I203M+p.I208M+p.L234V+p.D253E	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q203H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.S17N+p.M154L+p.N155H+p.V201I+p.D232N+p.L242LF	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q193H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.K14R+p.V31I+p.V32I+p.L45Q+p.L101I+p.T112V+p.T125A+p.G134N+p.I135V+p.K136T+p.Y143C+p.V201I+p.T206S+p.S230R+p.L234I+p.N254NS+p.R269K+p.D270H	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q195H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.E11D+p.K14R+p.S17T+p.V31I+p.L45V+p.A91S+p.L101I+p.T124A+p.E138Q+p.G140C+p.Q148R+p.V151I+p.K219N+p.N222K+p.L234I+p.V259I	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q201H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.E11D+p.V31I+p.G70R+p.I84V+p.L101I+p.S119P+p.T122I+p.N155H+p.G163E+p.V201I+p.D256E	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q198H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.K14R+p.S24G+p.D25E+p.S39C+p.I60IM+p.L63I+p.T97A+p.L101I+p.S119SR+p.T124N+p.T125A+p.I135V+p.E138T+p.G140S+p.Q148H+p.M154I+p.V165I+p.V201I+p.V259VI	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q202H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.E11D+p.S17C+p.L68V+p.L101I+p.T124N+p.T125A+p.I135V+p.G140A+p.Q148R+p.D253E+p.V281M	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q200H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.K14R+p.V31I+p.T97A+p.L101I+p.T112V+p.S119R+p.T124A+p.T125S+p.G134N+p.K136T+p.N155H+p.V165I+p.V201I+p.T206S+p.Y227F+p.L234I+p.S255N+p.D256E+p.S283G	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q197H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.S17N+p.R20K+p.M50I+p.V77A+p.L101I+p.T112I+p.T124A+p.T125A+p.K136Q+p.G193E+p.V201I+p.T206S+p.T218L+p.I220V+p.L234V+p.D256E+p.R263K+p.D279G+p.S283G	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q196H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.E11D+p.R20K+p.E92Q+p.V201I+p.K211R+p.S230SN+p.D232E+p.D256E	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q192H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.K14R+p.E69ED+p.E138K+p.G140S+p.Q148H+p.M154I+p.N155H+p.V201I	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q204H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.S17N+p.D25E+p.S119G+p.T122I+p.T124N+p.T125A+p.M154I+p.N155H+p.K156R+p.T206S+p.T218S	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q199H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.S17N+p.S24D+p.S39C+p.L45LQ+p.L101I+p.T124N+p.D167E+p.V201I+p.E212EA+p.R284RG+p.D286N	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, S24D, S39C, L45LQ, L101I, T124N, D167E, V201I, E212EA, R284RG, D286N.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.D6E+p.E10D+p.V31I+p.L101I+p.T124A+p.K156N+p.V201I+p.V249VI+p.M275V	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, E10D, V31I, L101I, T124A, K156N, V201I, V249VI, M275V.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.D6E+p.E10D+p.A23S+p.V31I+p.L101I+p.T124A+p.K156N+p.V201I+p.M275V	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, E10D, A23S, V31I, L101I, T124A, K156N, V201I, M275V.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.G4GR+p.R20K+p.T97A+p.T112V+p.I113V+p.T125A+p.Y143YC+p.H171Q+p.Y194YH+p.I200M+p.I203M+p.S230R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G4GR, R20K, T97A, T112V, I113V, T125A, Y143YC, H171Q, Y194YH, I200M, I203M, S230R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.S17N+p.I72V+p.L101I+p.G140S+p.Q148H+p.K156N+p.V201I+p.D207DG+p.I208L	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, I72V, L101I, G140S, Q148H, K156N, V201I, D207DG, I208L.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.S17N+p.I72V+p.L101LI+p.K156N+p.V201I+p.I208L+p.R228RK+p.D286DN	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, I72V, L101LI, K156N, V201I, I208L, R228RK, D286DN.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.S17N+p.I72V+p.L101LI+p.E138EK+p.G140GS+p.Q148QH+p.K156N+p.V201I+p.I208L+p.D286DN	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, I72V, L101LI, E138EK, G140GS, Q148QH, K156N, V201I, I208L, D286DN.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.K7R+p.S17N+p.V31I+p.T97A+p.L101I+p.T112A+p.T125A+p.Y143R+p.M154I+p.V201I	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K7R, S17N, V31I, T97A, L101I, T112A, T125A, Y143R, M154I, V201I.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.S17N+p.V31I+p.V79VI+p.L101I+p.I113IL+p.T124A+p.K211KR+p.L234I+p.A265AV	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V31I, V79VI, L101I, I113IL, T124A, K211KR, L234I, A265AV.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.S17N+p.V31I+p.E92EQ+p.T97TA+p.L101I+p.T124A+p.Y143R+p.A169AG+p.L234I	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V31I, E92EQ, T97TA, L101I, T124A, Y143R, A169AG, L234I.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.S17N+p.I72V+p.A98AT+p.L101I+p.G140GS+p.Q148QH+p.K156KN+p.V201I+p.I208L+p.D286DN	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, I72V, A98AT, L101I, G140GS, Q148QH, K156KN, V201I, I208L, D286DN.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.D6E+p.E10D+p.A23S+p.V31I+p.L101I+p.T124A+p.V151I+p.N155H+p.K156N+p.V201I+p.D232N+p.M275V	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, E10D, A23S, V31I, L101I, T124A, V151I, N155H, K156N, V201I, D232N, M275V.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.S17N+p.I72V+p.L101LI+p.E138EK+p.G140GS+p.Q148QH+p.N155ND+p.K156KN+p.V201I+p.I208L+p.D256DE+p.D286DN	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, I72V, L101LI, E138EK, G140GS, Q148QH, N155ND, K156KN, V201I, I208L, D256DE, D286DN.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.S17N+p.S24D+p.S39C+p.L45LQ+p.L101I+p.T124N+p.G140S+p.Q148H+p.D167E+p.V201I+p.E212A+p.R284G+p.D286N	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, S24D, S39C, L45LQ, L101I, T124N, G140S, Q148H, D167E, V201I, E212A, R284G, D286N.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.D25E+p.I72V+p.G140S+p.Q148H+p.V151I+p.K211R+p.K215N	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D25E, I72V, G140S, Q148H, V151I, K211R, K215N.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.S17N+p.V31I+p.V79VI+p.E92EQ+p.L101I+p.T124A+p.G140GS+p.Q148QR+p.N155NH+p.L234I	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V31I, V79VI, E92EQ, L101I, T124A, G140GS, Q148QR, N155NH, L234I.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.D6E+p.K14KR+p.S17N+p.R20K+p.D25E+p.S39C+p.L45X+p.T97TA+p.L101I+p.S119SR+p.T124A+p.V151VI+p.N155NH+p.K160T+p.G163GR+p.V201I+p.K211R+p.D288N	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, K14KR, S17N, R20K, D25E, S39C, L45X, T97TA, L101I, S119SR, T124A, V151VI, N155NH, K160T, G163GR, V201I, K211R, D288N.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.E10DG+p.E11D+p.V31I+p.S119P+p.T122I+p.T125A+p.V126M+p.A128AT+p.G140GS+p.V151VI+p.N155H+p.G163E+p.S195C+p.L234V+p.D279DN	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10DG, E11D, V31I, S119P, T122I, T125A, V126M, A128AT, G140GS, V151VI, N155H, G163E, S195C, L234V, D279DN.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.L63I+p.I73V+p.L74I+p.E96D+p.L101I+p.T112I+p.G140S+p.Q148H+p.I208L+p.D232E+p.L234LF	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63I, I73V, L74I, E96D, L101I, T112I, G140S, Q148H, I208L, D232E, L234LF.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.S147G	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S147G.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.E92G	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92G.
Key Molecule: HIV1 Integrase (HIV1 IT)				[10]
Molecule Alteration	Missense mutation		p.H51Y+p.I72V+p.I113V+p.L234V	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included H51Y, I72V, I113V, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.Q148R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.T66I+p.N155H	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.N155H	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.E92Q	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.Y143R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Y143R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.Q148K	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.T66K	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.N155H	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.E92Q+p.N155H	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)				[10]
Molecule Alteration	Missense mutation		p.I72V+p.I113V+p.L234V+p.R263K	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, L234V, R263K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.E92Q	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.E138K+p.Q148R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.E92Q+p.N155H	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.S153Y	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153Y.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.T66I+p.Q148R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.G140S+p.Q148R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140S, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.G140S+p.Q148H	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140S, Q148H.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.E92Q+p.Q148R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.Q148R+p.N155H	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148R, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)				[10]
Molecule Alteration	Missense mutation		p.H51Y+p.I72V+p.I113V+p.L234V+p.R263K	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included H51Y, I72V, I113V, L234V, R263K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.E138K+p.Q148K	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K, Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.T122I	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T122I.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.L74I	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74I.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.NULL	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included NULL.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.T66I+p.Q148K	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.S147G	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S147G.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.S153A	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153A.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.S119T	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S119T.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.Q95R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q95R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.E92G	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92G.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.E170A	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E170A.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.S119R+p.F121Y	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S119R, F121Y.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.T122I	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T122I.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.T97A+p.S119R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.G70R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G70R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.I72A+p.N155H	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72A, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.S147G	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S147G.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.S153F	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153F.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.S119R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.M50I	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M50I.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.A128T	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included A128T.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.G163R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G163R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.Q95K	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q95K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.E157Q	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E157Q.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.Q148R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.T97A+p.G163R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, G163R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.N155H	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.S153Y	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153Y.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.L234F	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L234F.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.H51Y	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included H51Y.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.T66I+p.R263K	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, R263K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.E92Q	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.E92Q	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.N155H	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.Y143R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Y143R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.Q146L	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q146L.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.Q146R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q146R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.R263K	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R263K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.S24G+p.N155H+p.D253E	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S24G, N155H, D253E.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.L45Q+p.T115H	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L45Q, T115H.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.Q148K	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.V151L	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V151L.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.E157K	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E157K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.E138K+p.Q148R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.S153Y	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153Y.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.R263K	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R263K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.T66K	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.S153Y+p.L234F	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153Y, L234F.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.S153F	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153F.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.S153Y	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153Y.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.Q148R+p.N155H	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148R, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.Q146I	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q146I.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.E92Q+p.G140A	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q, G140A.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.G140A+p.Q148R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140A, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.E138K+p.Q148K	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K, Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.T66I+p.E138K+p.Q148R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, E138K, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.G118R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G118R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.T97A+p.G118R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, G118R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.E138K+p.G140A+p.Q148R	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K, G140A, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.T66I+p.E138K+p.Q148K	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, E138K, Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[14]
Molecule Alteration	Missense mutation		p.S17N+p.T97A+p.L101I+p.T112M+p.S119P+p.T122I+p.T124N+p.T125A+p.G140S+p.Q148H	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, T97A, L101I, T112M, S119P, T122I, T124N, T125A, G140S, Q148H.
Key Molecule: HIV1 Integrase (HIV1 IT)				[14]
Molecule Alteration	Missense mutation		p.D6DE+p.E11D+p.S17T+p.A23V+p.V37I+p.I60IM+p.K71Q+p.A91AS+p.T97A+p.K111A+p.S119R+p.T124TN+p.T125Q+p.E138T+p.G140S+p.Q148H+p.I203M	Molecule Info
Resistant Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6DE, E11D, S17T, A23V, V37I, I60IM, K71Q, A91AS, T97A, K111A, S119R, T124TN, T125Q, E138T, G140S, Q148H, I203M.

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Aberration of the Drug's Therapeutic Target (ADTT)			Click to Show/Hide
Key Molecule: HIV1 Integrase (HIV1 IT)				[4]
Molecule Alteration	Missense mutation		p.S17N+p.V32I+p.I36V+p.D41G+p.M50L+p.I72V+p.L101I+p.T124N+p.T125A+p.I135V+p.Q148N+p.V201I+p.I208L+p.D256E	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Q148N, a novel integrase inhibitor resistance mutation associated with low-level reduction in elvitegravir susceptibility.
Key Molecule: HIV1 Integrase (HIV1 IT)				[4]
Molecule Alteration	Missense mutation		p.S17N+p.V32I+p.I36V+p.D41G+p.M50L+p.I72V+p.L101I+p.T124N+p.T125A+p.I135V+p.G140S+p.Q148N+p.V201I+p.I208L+p.D256E	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Q148N, a novel integrase inhibitor resistance mutation associated with low-level reduction in elvitegravir susceptibility.
Key Molecule: HIV1 Integrase (HIV1 IT)				[4]
Molecule Alteration	Missense mutation		p.I72V+p.I113V+p.Q148H+p.V151I+p.L234V	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Q148N, a novel integrase inhibitor resistance mutation associated with low-level reduction in elvitegravir susceptibility.
Key Molecule: HIV1 Integrase (HIV1 IT)				[4]
Molecule Alteration	Missense mutation		p.I72V+p.I113V+p.G140S+p.Q148N+p.V151I+p.L234V	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Q148N, a novel integrase inhibitor resistance mutation associated with low-level reduction in elvitegravir susceptibility.
Key Molecule: HIV1 Integrase (HIV1 IT)				[4]
Molecule Alteration	Missense mutation		p.I72V+p.I113V+p.Q148N+p.V151I+p.L234V	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Q148N, a novel integrase inhibitor resistance mutation associated with low-level reduction in elvitegravir susceptibility.
Key Molecule: HIV1 Integrase (HIV1 IT)				[3]
Molecule Alteration	Missense mutation		p.I72V+p.I113V+p.E138K+p.V151I+p.L234V	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
In Vitro Model	BL21 cells	Cerebrospinal fluid	Homo sapiens (Human)	CVCL_M639
Experiment for Molecule Alteration	Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[3]
Molecule Alteration	Missense mutation		p.E11D+p.K14R+p.S24N+p.V31I+p.M50I+p.L74I+p.A91E+p.L101I+p.T112V+p.S119R+p.T124A+p.T125A+p.A133T+p.G134N+p.I135V+p.K136T+p.E138K+p.V165I+p.V201I+p.T206S+p.T218I+p.L234I+p.S283D	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
In Vitro Model	BL21 cells	Cerebrospinal fluid	Homo sapiens (Human)	CVCL_M639
Experiment for Molecule Alteration	Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[6]
Molecule Alteration	Missense mutation		p.S17N+p.M50L+p.I72V+p.Q95QH+p.T112V+p.I113V+p.T124A+p.T125A+p.G134D+p.V201I+p.Q221QKR+p.L234I+p.D256E	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	MT-2 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2631
	MT-4 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2632
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[6]
Molecule Alteration	Missense mutation		p.I5V+p.S17N+p.M50L+p.E69G+p.I72V+p.T112I+p.I113V+p.T124A+p.T125A+p.T174A+p.V201I+p.T218I+p.L234I+p.D256E	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	MT-2 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2631
	MT-4 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2632
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[6]
Molecule Alteration	Missense mutation		p.K42Q+p.L101I+p.T112V+p.T124A+p.T125A+p.K136Q+p.G163R+p.V201I+p.L234I+p.R269K+p.D278A+p.S283G	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	MT-2 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2631
	MT-4 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2632
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[6]
Molecule Alteration	Missense mutation		p.K14R+p.V31I+p.I72V+p.T112V+p.I113V+p.T124A+p.T125A+p.G134N+p.I135V+p.D167E+p.V201I+p.T206S+p.I208L+p.N222K+p.L234I+p.A265V+p.R269K+p.S283G	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	MT-2 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2631
	MT-4 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2632
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[6]
Molecule Alteration	Missense mutation		p.K14R+p.V31I+p.L74I+p.L101I+p.T112V+p.T124A+p.T125A+p.G134N+p.I135V+p.K136T+p.H171Q+p.V201I+p.T206S+p.I208M+p.T218I+p.L234I+p.A265V+p.R269K+p.D286N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	MT-2 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2631
	MT-4 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2632
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[6]
Molecule Alteration	Missense mutation		p.L101I+p.T122I+p.T124N+p.A265V	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	MT-2 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2631
	MT-4 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2632
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[6]
Molecule Alteration	Missense mutation		p.S17N+p.I72V+p.I84V+p.T124A+p.M154I+p.K173R	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	MT-2 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2631
	MT-4 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2632
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[6]
Molecule Alteration	Missense mutation		p.S17N+p.L28I+p.P30A+p.I84L+p.S119T+p.T124A+p.K136Q+p.V165I+p.I200T+p.V201I+p.K211R+p.T218I+p.L234V+p.D256E+p.S283G	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	MT-2 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2631
	MT-4 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2632
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[6]
Molecule Alteration	Missense mutation		p.E11D+p.D25E+p.V31I+p.F100Y+p.L101I+p.T112V+p.S119P+p.K136Q+p.V201I+p.T218I+p.L234I+p.A265V+p.R269K+p.D278A+p.S283G	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	MT-2 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2631
	MT-4 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2632
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[6]
Molecule Alteration	Missense mutation		p.K14R+p.A21T+p.A23V+p.S39N+p.I72V+p.T112V+p.T124A+p.T125A+p.G134N+p.I135V+p.K136R+p.D167E+p.V201I+p.L234I+p.S283G	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	MT-2 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2631
	MT-4 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2632
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[6]
Molecule Alteration	Missense mutation		p.K14R+p.A21T+p.V31I+p.V32I+p.M50I+p.I72V+p.T112V+p.T124A+p.T125A+p.G134N+p.I135V+p.K136R+p.D167E+p.V201I+p.T206S+p.L234I+p.S283G	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	MT-2 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2631
	MT-4 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2632
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[6]
Molecule Alteration	Missense mutation		p.V88I+p.M154I	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	MT-2 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2631
	MT-4 cells	Umbilical cord blood	Homo sapiens (Human)	CVCL_2632
Experiment for Molecule Alteration	PCR; DNA sequencing assay
Experiment for Drug Resistance	PhenoSense assay
Mechanism Description	Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.Q148H+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E295Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.Q148R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E294Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.N155H+p.E157Q+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E288Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.N155H+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E285Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.M50I+p.I72V+p.S123G+p.T124A+p.K127R+p.N155H+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E282Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148R+p.E157Q+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E258Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.Q148R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E257Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.M50I+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E250Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S147G+p.E157Q+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E280Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.S147G+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E262Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.M50I+p.I72V+p.S123G+p.T124A+p.K127R+p.S147G+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E274Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.E157Q+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E289Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.E92Q+p.S119P+p.S123G+p.T124A+p.K127R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E281Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.M50I+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E276Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.T66I+p.I72V+p.S123G+p.T124A+p.K127R+p.E157Q+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E232Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.T66I+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E228Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.M50I+p.T66I+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E231Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E170A+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E270Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G163K+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E256Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E157Q+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E273Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E157K+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E284Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S153Y+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E292Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S153F+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E290Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S153A+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E269Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.V151L+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E283Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.V151A+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E249Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E279Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146P+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E234Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146L+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E275Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146K+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E248Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146I+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E293Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.P145S+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E227Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E247Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140C+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E233Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140A+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E244Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E138K+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E246Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E138A+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E255Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.A128T+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E268Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.Q95R+p.S123G+p.T124A+p.K127R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E261Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.Q95K+p.S123G+p.T124A+p.K127R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E267Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72T+p.S123G+p.T124A+p.K127R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E254Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72N+p.S123G+p.T124A+p.K127R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E241Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72A+p.S123G+p.T124A+p.K127R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E240Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.L68V+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E239Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.L68I+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E243Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.H51Y+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E272Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N+p.R263K	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E287Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.N155H+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E278Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E238Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148K+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E237Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148H+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E245Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S147G+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E260Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Y143R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E271Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Y143H+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E266Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Y143C+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E253Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E277Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.I72V+p.E92G+p.S123G+p.T124A+p.K127R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E286Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.T66K+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E291Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.T66I+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E230Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.E10D+p.T66A+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E229Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.S17N+p.S39R+p.L45V+p.M50ML+p.T66A+p.V75I+p.L101I+p.T124A+p.K127R+p.S147SG+p.G163K+p.V201I	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q187H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.A23T+p.S24G+p.D25E+p.L28I+p.I72V+p.T124A+p.Q148R+p.V165I+p.L172LF+p.H183HP+p.Q209QP+p.A239AT	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q186H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.K7KR+p.S17N+p.I72V+p.I84L+p.T97A+p.L101I+p.T112I+p.S119P+p.T122I+p.T124N+p.T125A+p.K136Q+p.Y143R+p.V201I+p.A205S+p.K211R+p.T218L+p.L234V+p.D256E+p.I268L+p.D270H	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q188H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.K14R+p.S24H+p.V31I+p.L68I+p.I73V+p.E92Q+p.L101I+p.T112V+p.S119T+p.T124G+p.T125A+p.G134N+p.K136T+p.V165I+p.V201I+p.T206S+p.L234I+p.D256E+p.S283G	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q190H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.G59D+p.I60V+p.E138K+p.Q148R+p.K173R+p.T218S+p.S230N+p.M275S+p.C280S	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q189H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[7]
Molecule Alteration	Missense mutation		p.K14R+p.L101V+p.T112I+p.T125V+p.N155H+p.E157Q+p.K160Q+p.G193E+p.S230N+p.L234I+p.A265V+p.D279G	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	TZM-bl cells	Uterus	Homo sapiens (Human)	CVCL_B478
Experiment for Molecule Alteration	Population sequencing of the integrase region assay
Experiment for Drug Resistance	TZM-bl cell line-based phenotypic assay
Mechanism Description	In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q191H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.G163R	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E265Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.F121Y	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E236Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.S119T	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E259Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.S119R	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E264Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.S119P	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E252Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.S119G	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E251Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.L74M	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E242Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.M50I	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E263Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[1]
Molecule Alteration	Missense mutation		p.T97A	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	IN sequencing assay
Experiment for Drug Resistance	SDMs and phenotyping assay
Mechanism Description	Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E235Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.T66A	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66A.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.T66I	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.Q148H	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148H.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.T97A	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.Q148H	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148H.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.T66I+p.E92Q	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, E92Q.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.Y143C	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Y143C.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.Q148K	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[8]
Molecule Alteration	Missense mutation		p.Q148R	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[9]
Molecule Alteration	Missense mutation		p.Y143H	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Y143H.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.T66I	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.P145S	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included P145S.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.T66A	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66A.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.T66I	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.Q148H	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148H.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.L74M+p.T97A+p.S119T	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119T.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.L74M+p.T97A+p.S119G	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119G.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.L74M	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.Q146P	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q146P.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.G140C	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140C.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.L74M+p.T97A	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.T97A+p.G118R+p.S119R	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, G118R, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.L74M+p.T97A+p.S119P	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119P.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.T97A+p.S119T	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119T.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.T97A+p.S119P	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119P.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.L74M+p.T97A	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.T97A	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.T97V	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97V.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.T97I	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97I.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.Q148R	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.G140A	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140A.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.NULL	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included NULL.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.T66I+p.S153F	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, S153F.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.F121Y	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included F121Y.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.L68V	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L68V.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.T97A	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.I72N	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72N.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.I72A	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72A.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.L74M+p.S119P	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, S119P.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.L74M	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.T97A+p.S119G	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119G.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.L74I+p.T97A	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74I, T97A.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.M50I+p.T97A	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M50I, T97A.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.A91E	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included A91E.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.T97S	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97S.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.I72A	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72A.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.E138K	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.Q148K	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.G140A	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140A.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.L74M	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.L68I	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L68I.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.L74M+p.T97A+p.S119R	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.E157K	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E157K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.V151A	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V151A.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.Y143C	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Y143C.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.Q146K	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q146K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.G140S	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140S.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.L74M+p.S119R	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.L74M+p.T97A+p.S119R	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[11]
Molecule Alteration	Missense mutation		p.L74M+p.S119R	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)				[12]
Molecule Alteration	Missense mutation		p.G140E	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140E.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.Y143H	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Y143H.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.S119G	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S119G.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.E138A	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138A.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.I72T	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72T.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.E138K	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.G163K	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G163K.
Key Molecule: HIV1 Integrase (HIV1 IT)				[13]
Molecule Alteration	Missense mutation		p.S119P	Molecule Info
Sensitive Disease	Human immunodeficiency virus infection [ICD-11: 1C62.0]			Disease Info
Experimental Note	Discovered Using In-vivo Testing Model
Experiment for Molecule Alteration	Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for Drug Resistance	PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description	Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S119P.

References

Ref 1	Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-na ve individuals. J Med Virol. 2019 Dec;91(12):2188-2194. doi: 10.1002/jmv.25564. Epub 2019 Aug 20.
Ref 2	Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother. 2015 Feb;70(2):405-11. doi: 10.1093/jac/dku387. Epub 2014 Oct 3.
Ref 3	Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase. J Virol. 2015 Mar;89(6):3163-75. doi: 10.1128/JVI.03353-14. Epub 2014 Dec 31.
Ref 4	Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility. AIDS Res Hum Retroviruses. 2016 Jul;32(7):702-4. doi: 10.1089/AID.2016.0038. Epub 2016 Apr 19.
Ref 5	The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B. AIDS. 2015 Jul 31;29(12):1459-66. doi: 10.1097/QAD.0000000000000752.
Ref 6	Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob Agents Chemother. 2016 Nov 21;60(12):7086-7097. doi: 10.1128/AAC.01474-16. Print 2016 Dec.
Ref 7	Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations. Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01717-19. doi: 10.1128/AAC.01717-19. Print 2019 Dec 20.
Ref 8	The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adultsJ Acquir Immune Defic Syndr. 2012 Nov 1;61(3):297-301. doi: 10.1097/QAI.0b013e31826bfd02.
Ref 9	Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitnessAntimicrob Agents Chemother. 2013 Jun;57(6):2654-63. doi: 10.1128/AAC.02568-12. Epub 2013 Mar 25.
Ref 10	Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressureRetrovirology. 2013 Feb 22;10:22. doi: 10.1186/1742-4690-10-22.
Ref 11	Bictegravir Resistance Profile: Data for External Experts.
Ref 12	Integrase Inhibitor Resistance Selections Initiated with Drug Resistant HIV-1.
Ref 13	Pre-existing HIV-1 integrase polymorphisms do not impact treatment response to elvitegravir-containing fixed-dose combination regimens in treatment-naive patients.
Ref 14	Rapid development of high level resistance to dolutegravir with emergence of T97A mutation in two treatment experienced individuals with baseline partial sensitivity to dolutegravir.

visits since 2022

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.

Drug Information

Cite DRESIS

About

Correspondence

Prof. Feng ZHU (zhufeng@zju.edu.cn)